Eiko Lifesciences Q1 results: revenue up about 90 percent standalone, 56 percent consolidated

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹50.00

prior close

₹49.58

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+0.4% vs market

Specialty Chemicals peers, median of 93sector-0.4%+1.2% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 1.2 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+0.7

15m

+0.7

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8+0.4+0.4-0.4+1.2

Next day

-0.0+0.5-0.5-0.3+0.3

-4.0+0.6-4.6-0.2-3.8

-1.2+0.7-1.9-0.6-0.7

-2.1+1.1-3.2-0.7-1.4

-3.2+0.5-3.7-1.5-1.7

-5.4+1.3-6.7-0.9-4.5

15d

-7.2+0.5-7.7+0.2-7.4

-12.0-0.8-11.2-1.4-10.6

-3.1-0.9-2.2-2.5-0.6

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 93Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited results (quarter ended 30 June 2026). Standalone revenue rose to Rs 1,417.81 lakhs from Rs 745.23 lakhs YoY, about 90 percent up. Standalone PAT grew to Rs 106.44 lakhs from Rs 69.22 lakhs, around 54 percent. Consolidated revenue rose to Rs 1,674.88 lakhs from Rs 1,071.15 lakhs, about 56 percent up. Consolidated PAT rose to Rs 150.83 lakhs from Rs 111.74 lakhs, around 35 percent up. PSV Jain gave unmodified review.

Likely market impact

Strong revenue and profit growth on both standalone and consolidated basis. New logistics segment adds revenue. Unmodified audit opinion.